Our Vision

We aim to redefine what's possible in drug discovery by unlocking the therapeutic potential of synthetic macrocycles (unnatural products) to build a robust, diverse pipeline of valuable medicines.

Leadership

Cameron Pye

Co-Founder & CEO

UC Santa Cruz PhD in organic chemistry who co-founded UNP during his final year of doctoral work, turning his research on macrocycle cell permeability in the Lokey Lab into a platform to drug the undruggable.

Lindsay Young

VP Human Resources

Lindsay brings broad experience across the HR landscape—people strategy, compliance, talent acquisition, compensation, and building amazing places to work. Before joining Unnatural Products, Lindsay served as the Head of Human Resources at Tempest Therapeutics, and earlier in her career she held various positions in commercial operations at Cepheid and CV Therapeutics.

Joshua Schwocher

Co-Founder & CSO

Macrocycle and cyclic peptide expert with a PhD from UC Santa Cruz, whose doctoral collaborations with Pfizer and Eli Lilly on beyond-rule-of-5 pharmacokinetics laid the scientific foundation for UNP's drug discovery platform.

Henry Johnson

VP Medicinal Chemistry and CMC

Henry W.B. Johnson, PhD, is a drug discovery leader with 20+ years of experience advancing small molecule therapeutics. He has led multidisciplinary R&D teams and contributed to the advancement of several clinical assets from early discovery through late-stage development.

Simon Bailey

COO & President of R&D

Veteran drug discovery leader with 25+ years of experience across Pfizer, Intercept Pharmaceuticals, and Plexium, and recipient of the ACS Hero of Chemistry award for his role in the discovery of Lorbrena™